Epigenetic control of variation and stochasticity in metabolic disease

Panzeri, Ilaria; Pospisilik, John Andrew

doi:10.1016/j.molmet.2018.05.010

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Epigenetic control of variation and stochasticity in metabolic disease

MPS-Authors

Panzeri, Ilaria
Department of Epigenetics, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

/persons/resource/persons198873

Pospisilik, John Andrew
Department of Epigenetics, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Panzeri, I., & Pospisilik, J. A. (2018). Epigenetic control of variation and stochasticity in metabolic disease. Molecular Metabolism, 14, 26-38. doi:10.1016/j.molmet.2018.05.010.

Cite as: https://hdl.handle.net/21.11116/0000-0002-4866-B

Abstract

BACKGROUND:
The alarming rise of obesity and its associated comorbidities represents a medical burden and a major global health and economic issue. Understanding etiological mechanisms underpinning susceptibility and therapeutic response is of primary importance. Obesity, diabetes, and metabolic diseases are complex trait disorders with only partial genetic heritability, indicating important roles for environmental programing and epigenetic effects.

SCOPE OF THE REVIEW:
We will highlight some of the reasons for the scarce predictability of metabolic diseases. We will outline how genetic variants generate phenotypic variation in disease susceptibility across populations. We will then focus on recent conclusions about epigenetic mechanisms playing a fundamental role in increasing variability and subsequently disease triggering.

MAJOR CONCLUSIONS:
Currently, we are unable to predict or mechanistically define how "missing heritability" drives disease. Unravelling this black box of regulatory processes will allow us to move towards a truly personalized and precision medicine.